Inventi Rapid: Medicine

Inventi:hrmc/47569/23

Identification of Bioactive Compounds as Potent Inhibitors in the Treatment of Polycystic Ovary Syndrome through Computational Assessment

Polycystic ovary syndrome (PCOS) is one of the most common disorders that occur in women of any age due to an endocrine hormone imbalance. There is an urgent need for the development of novel natural PCOS medications free from adverse effects because the underlying cause of this condition has not yet been discovered. It was observed from a literature review on medicinal plant species that the phytochemicals present in the plants have the ability to increase the function of hormones for fertility. The goal of the ongoing research is to identify novel medication candidates from the medicinal plants that could be used to treat the target PCOS protein. An assessment of the medicinal plants revealed 145 phytochemicals that have been discovered through research. After in-silico screening for its drug likeness and structural reaction towards biological functions, only 23 compounds of the medicinal plants demonstrated the oral drug response, while other compounds failed to pass oral drug tests. Using docking studies, these compounds were further examined for their ability to bind to the PCOS protein Cytochrome P450 (CYP). The current findings suggest that the strongest binding affinity interactions with the target protein are only present in two compound. Based on the findings of this study, the predicted plant components can be identified and extracted for additional in-vitro and in-vivo testing to establish the safe dosage for PCOS patients....